XF-73 Momentum
Destiny’s recent business update noted the continued partnering interest on XF-73 Nasal – its now lead product for the prevention of post-surgical staphylococcal infections now that NTCD-M3 has been partnered in the US – and the active discussions with potential partners who have access to the data room. The announcement also implied that the data room would include details and the requirements for the XF-73 Nasal clinical trial plan that has been agreed with the US FDA and the EMA for Europe.The focus of the recent business update was the partnering of XF-73 Nasal which is the priority of the interim CEO and the new Consultant Head of Business Development. With the new hire’s experience in the US, like NTCD-M3, it is likely that the first (or only, if global) XF-73 Nasal licensing transaction will be for the US market because our estimates of XF-73’s peak sales are just over $2bn, with 97% of them in the US.
Their more recent announcement was on the positive Scientific Advisory Board (SAB) comments on XF-73 Nasal. Destiny could not have described the meeting as “positive” had the SAB not reviewed and endorsed the clinical program and endpoints for XF-73 Nasal’s Phase 3 studies. This will give both investors and potential partners additional reassurance.
Our fair value for Destiny Pharma plc remains at £254.7m (or 279 pence per share).
Destiny Pharma is engaged in the discovery, development and commercialization of antimicrobials that have properties to improve outcomes for patients and the delivery of medical care into the future.
Equity Development enables companies to become better understood and supported by investors. Since our launch in 1996 we have consistently focused on helping our clients improve their communication and relationships with both existing and potential shareholders. Our clients have come from a wide variety of sectors and domiciles, are both private and quoted and range in size from micro-cap to $multi-billions. We offer free access to company research notes written by experienced analysts. These notes include detailed forecasts, financial models and a fair value. We host regular Private Investor Forums at which investors have the opportunity to hear company directors present, and to ask questions. These are free to attend. We broadcast live Webinars with company management that include active Q&A. We also make the recordings available online. We arrange face to face meetings between private investors and company management. We are active users of Twitter, commenting daily on company news, share price moves, Directors’ Dealings, Equity Development Research Notes & Events.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.